The once-invincible organization PhRMA used to raise hell. Lately, however, the lobbying group's rhetoric is on mute. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

PhRMA, once invincible in Washington, has lost its edge By Rachel Cohrs Mike Reddy for STAT PhRMA has a reputation in Washington for might, for money, for scorched-earth tactics, and for fighting even the tiniest of policy changes. Over the last year, however, something changed. The once titanic lobbying powerhouse has lost its edge. STAT spoke with 22 drug industry lobbyists, health care consultants, and academic experts to understand the tone shift and the defeat, and what they mean for PhRMA’s future. Its aura of invincibility has been punctured, and its hubris softened with a touch of humility. The once formidable group is, in many ways, laying low. Read More Sponsored insight by STAT+ In-depth analysis of biopharma and the life sciences Sign up for STAT+ to access in-depth analysis of biopharma, inside intelligence from Capitol Hill, the latest on medicine tech, and more. Subscribe today to and start your free 30-day trial. More great reads from STAT this week On the long road to treating Huntington’s genetic stutter, scientists return to overlooked clues By Megan Molteni ‘A constant information lag’: The troubled recall of Philips CPAP machines underscores flaws in device oversight By Brittany Trang In Philadelphia, ‘tranq’ is leaving drug users with horrific wounds. Other communities are bracing for the same By Andrew Joseph Alzheimer’s researchers try out an unfamiliar sensation: optimism By Jonathan Wosen and Damian Garde ‘This actually changes everything’: Altered image in 1999 paper raises potential peril for Stanford president By Olivia Goldhill and Megan Molteni ‘The hospital never supported the midwives’: As more birth centers open, their viability hinges on nearby hospitals By Theresa Gaffney Lessons from a thriving physical therapist to a younger self just learning about multiple sclerosis By Isabella Cueto Former Merck CEO: Democracy and the drug industry are both in danger By Matthew Herper Opinion: Minimizing administrative harm: a key step to improving health care By Walter J. O’Donnell Saturday, December 3, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser